Moreover, MΦ reprogramming overcomes AML blast resistance to two standard anti-AML therapies, the FMS-like tyrosine kinase 3 (FLT3) inhibitor midostaurin and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. The gene discussed is FLT3; the disease is acute myeloid leukemia.